GLP Watchdog

Rybelsus vs Ozempic: Rybelsus Tablets, Being Discontinued in the US, vs Ozempic Pens

Rybelsus (semaglutide (oral), Novo Nordisk) vs Ozempic (semaglutide (subcutaneous), Novo Nordisk)

Last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

The molecule is the same, and the route is the difference. Ozempic is injected once a week. Rybelsus is swallowed once a day before breakfast, with nothing else for half an hour, because the SNAC absorption enhancer works only when the stomach is empty. In the US, Rybelsus is being discontinued: on June 4, 2026 the FDA listed all three strengths as discontinued, to be replaced by Ozempic tablets, the same semaglutide reformulated at 1.5, 4 and 9 mg and on sale since May 4, 2026. Under the shared label, 7 mg of Rybelsus corresponds to 4 mg of Ozempic tablets and 14 mg to 9 mg, and the label says the two are not substitutable milligram for milligram. On heart outcomes, SUSTAIN-6 found the injection superior to placebo for major cardiovascular events (HR 0.74). For the tablet, PIONEER 6 showed noninferiority (HR 0.79) and the later SOUL trial showed superiority (HR 0.86), which added a cardiovascular indication to the tablet label. The Ozempic pen costs $349 to $499 a month through NovoCare self-pay, and Ozempic tablets $149 to $299 by strength. The choice is between a daily tablet routine and a weekly injection.

Side-by-side comparison

Rybelsus vs Ozempic, side by side
FieldRybelsusOzempic
Route & frequencyOral tablet, once daily (empty stomach)Subcutaneous injection, once weekly
FDA-approved dose range3 mg → 7 mg → 14 mg daily (Ozempic tablets, its US replacement: 1.5 → 4 → 9 mg)0.25 → 0.5 → 1 → 2 mg weekly
A1C reduction (monotherapy)−0.9% to −1.4% / 26 wk (PIONEER 1, 14 mg)−1.4% to −1.6% / 30 wk (SUSTAIN 1, 1 mg)
Head-to-head vs injectable GLP-1Oral sema 14 mg −1.2% A1C; liraglutide 1.8 mg −1.1% (PIONEER 4)Not the comparator in PIONEER 4 (oral vs liraglutide)
Weight loss (max dose)−3.7 kg at 26 wk (PIONEER 1, 14 mg; placebo −1.4 kg)−4.5 to −6.5 kg at 30-40 wk (SUSTAIN program, 1-2 mg)
Cardiovascular outcome trialMACE HR 0.86 (superior; SOUL, 14 mg). PIONEER 6 had shown non-inferiority (HR 0.79)MACE HR 0.74 (superior; SUSTAIN-6)
MechanismGLP-1 receptor agonist (semaglutide + SNAC absorption enhancer)GLP-1 receptor agonist (semaglutide)
What it costs if you pay cash$149–$299/mo self-pay as Ozempic tablets, its US replacement$349–$499/mo NovoCare self-pay (pen)

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

Rybelsus — semaglutide (oral)

from $47 /mo

463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.

Where to get semaglutide — a selection of sellers, not a price ranking

Ozempic — semaglutide (subcutaneous)

from $47 /mo

463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.

Where to get semaglutide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, Rybelsus or Ozempic?

On the trial evidence, Ozempic. Rybelsus recorded −3.7 kg at 26 wk (PIONEER 1, 14 mg; placebo −1.4 kg) and Ozempic −4.5 to −6.5 kg at 30-40 wk (SUSTAIN program, 1-2 mg), and the head-to-head comparison put Rybelsus at Oral sema 14 mg −1.2% A1C; liraglutide 1.8 mg −1.1% (PIONEER 4) against Ozempic at Not the comparator in PIONEER 4 (oral vs liraglutide). A head-to-head is the strongest form of this evidence because both arms run under one protocol — separate trials are not directly comparable however alike they look.

Are Rybelsus and Ozempic the same drug?

Chemically, yes — both are semaglutide (oral). They are sold under different names for different approved uses, and usually at different doses and different prices. That is a labeling and commercial distinction, not a pharmacological one, which is why a prescription for one is not automatically interchangeable with the other at the pharmacy counter.

Is Rybelsus or Ozempic cheaper?

On the manufacturers' own cash pricing: Rybelsus at $149–$299/mo self-pay as Ozempic tablets, its US replacement, Ozempic at $349–$499/mo NovoCare self-pay (pen). That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Does either one have better cardiovascular evidence?

Neither has a clear edge. Rybelsus: MACE HR 0.86 (superior; SOUL, 14 mg). PIONEER 6 had shown non-inferiority (HR 0.79). Ozempic: MACE HR 0.74 (superior; SUSTAIN-6). This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.

What does a compounded version of each actually cost?

Compounders sell the molecule, not either brand, so one figure covers both: across the 734 sellers in this register, the cheapest standing monthly cash price we hold for compounded semaglutide is $47 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Rybelsus to Ozempic?

People move between them regularly, since it is the same molecule — but the dose ladders differ, so a prescriber has to map where you land rather than matching the number. Do not assume your current dose transfers.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31186300.
  2. 2.Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019. PMID: 31186120.
  3. 3.Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). N Engl J Med. 2019. PMID: 31185157.
  4. 4.Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016. PMID: 27633186.
  5. 5.Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets — Prescribing Information (revised January 2026). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  6. 6.Novo Nordisk. OZEMPIC (semaglutide) injection — Prescribing Information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  7. 7.McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. 2025. PMID: 40162642.
  8. 8.Novo Nordisk. Ozempic (semaglutide) pill available in the US starting May 4 (press release, May 1, 2026). Novo Nordisk US newsroom. 2026. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916540
  9. 9.U.S. Food and Drug Administration. Drug Shortages database: Semaglutide Tablet (Rybelsus 3 mg, 7 mg, 14 mg), discontinuation posted June 4, 2026. FDA. 2026. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Tablet&st=d&tab=tabs-2

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.